Cyclo Therapeutics, Inc. (CYTH)
$
0.72
Key metrics
Financial statements
Free cash flow per share
-0.9913
Market cap
23.6 Million
Price to sales ratio
21.9153
Debt to equity
0.2172
Current ratio
1.4547
Income quality
0.8069
Average inventory
254.4 Thousand
ROE
-7.3048
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, is focused on developing cyclodextrin-based products aimed at treating various diseases. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. Additionally, it earned an interest income of $0.00 showcasing its financial investments. The total costs and expenses for the company are $21,126,462.00 reflecting its overall spending. The operating income ratio is -$18.63 indicating the company's operational profitability margin. Furthermore, the earnings per share (EPS) is reported at -$1.23 indicating the company's profitability on a per-share basis. The lead drug candidate, Trappsol Cyclo, is currently in Phase III clinical trials for the treatment of Niemann-Pick Type C disease, while the company also explores its application in the treatment of Alzheimer's disease. Beyond its drug development efforts, Cyclo Therapeutics sells cyclodextrins and related products to the pharmaceutical, nutritional, and various other industries, primarily for use in diagnostics and specialty drugs. Founded in 1990 and based in Gainesville, Florida, the company was formerly known as CTD Holdings, Inc., a name it adopted in September 2019. With regard to its market position, the stock is affordable at $0.72 suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,761,627.00 indicating lower market activity. With a market capitalization of $23,589,778.00 the company is classified as a small-cap player, which often means it has significant potential for growth and innovation. Cyclo Therapeutics is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within its focus areas. The blend of its development pipeline and strategic market positioning highlights the company's commitment to advancing treatments for unmet medical needs while maintaining a financially prudent approach.
What is Cyclo Therapeutics, Inc. (CYTH)'s stock forecast?
Analysts predict Cyclo Therapeutics, Inc. stock to fluctuate between $0.55 (low) and $1.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cyclo Therapeutics, Inc.'s market capitalization?
As of 2025-03-25, Cyclo Therapeutics, Inc.'s market cap is $23,589,778, based on 32,736,300 outstanding shares.
How does Cyclo Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cyclo Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cyclo Therapeutics, Inc. (CYTH) stock?
To buy Cyclo Therapeutics, Inc. (CYTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CYTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Cyclo Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Cyclo Therapeutics, Inc. stock ever split?
Cyclo Therapeutics, Inc.'s last stock split was 1:100 on 2020-12-09.
How did Cyclo Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,076,405 | EPS: -$1.23 | Growth: -32.04%.
Where can I find Cyclo Therapeutics, Inc.'s investor relations reports?
Visit https://www.cyclotherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cyclo Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Cyclo Therapeutics, Inc. stock?
All-time high: $8.49 (2021-08-05) | All-time low: $0.55 (2024-12-31).
What are the key trends affecting Cyclo Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
a year ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.
businesswire.com
a year ago
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) at the 21st Annual WOR.
prnewswire.com
a year ago
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Liberty TripAdvisor Holdings, Inc. (OTCMKTS: LTRPA, LTRPB)'s sale to Tripadvisor, Inc. If you are a Liberty TripAdvisor shareholder, click here to learn more about your legal rights and options . Cyclo Therapeutics, Inc. (NASDAQ: CYTH)'s merger with Rafael Holdings, Inc. If you are a Cyclo shareholder, click here to learn more about your rights and options.
globenewswire.com
a year ago
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Niemann-Pick disease - Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann-Pick disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
zacks.com
a year ago
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
prnewswire.com
a year ago
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
prnewswire.com
a year ago
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.
accesswire.com
a year ago
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Vector Group Ltd.
businesswire.com
a year ago
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2024 and provided a business update. “The second quarter represents a transformative time for the Company with the achievement of a landmark milestone -- the.
zacks.com
a year ago
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
See all news
